alprostadil liposome / CSPC Pharma - LARVOL DELTA

A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI (clinicaltrials.gov) - P2 | N=132 | Terminated | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | N=368 ➔ 132 | Trial completion date: May 2024 ➔ Jan 2024 | Recruiting ➔ Terminated; Voluntarily suspended the trial due to strategic adjustments

Enrollment change • Trial completion date • Trial termination • Acute Kidney Injury • Nephrology • Renal Disease

A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI (clinicaltrials.gov) - P2 | N=368 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Kidney Injury • Nephrology • Renal Disease • CST3 • IL6